Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cytosorbents (CTSO) Return on Capital Employed (2016 - 2026)

Cytosorbents filings provide 14 years of Return on Capital Employed readings, the most recent being 5.12% for Q4 2025.

  • On a quarterly basis, Return on Capital Employed rose 3844.0% to 5.12% in Q4 2025 year-over-year; TTM through Dec 2025 was 5.12%, a 3844.0% increase, with the full-year FY2025 number at 5.01%, up 3578.0% from a year prior.
  • Return on Capital Employed hit 5.12% in Q4 2025 for Cytosorbents, up from 37.43% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 5.12% in Q4 2025 to a low of 86.14% in Q4 2023.
  • Median Return on Capital Employed over the past 5 years was 45.11% (2022), compared with a mean of 46.28%.
  • Biggest five-year swings in Return on Capital Employed: soared 5692bps in 2021 and later plummeted -4285bps in 2022.
  • Cytosorbents' Return on Capital Employed stood at 28.94% in 2021, then plummeted by -105bps to 59.43% in 2022, then tumbled by -45bps to 86.14% in 2023, then surged by 49bps to 43.56% in 2024, then soared by 88bps to 5.12% in 2025.
  • The last three reported values for Return on Capital Employed were 5.12% (Q4 2025), 37.43% (Q3 2025), and 39.77% (Q2 2025) per Business Quant data.